Dbv Technologies SA (NASDAQ:DBVT)

2.64
Delayed Data
As of Aug 12
 -0.03 / -1.12%
Today’s Change
1.15
Today|||52-Week Range
5.99
+65.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$496.5M

Company Description

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Contact Information

DBV Technologies SA
177-181, avenue Pierre Brossolette
Montrouge Ile-de-france 92120
P:(315) 542-7878
Investor Relations:
(857) 529-2363

Employees

Shareholders

Other institutional13.11%
Individual stakeholders12.48%
Mutual fund holders1.40%

Top Executives

Daniel TasséChief Executive Officer & Executive Director
Sébastien RobitailleChief Financial Officer
Pharis MohideenChief Medical Officer
Pascal WotlingChief Technical Operations Officer
Pascale EhouarnChief Engineering, Manufacturing & Supply Officer